WO2007134158A2 - Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy - Google Patents
Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy Download PDFInfo
- Publication number
- WO2007134158A2 WO2007134158A2 PCT/US2007/068650 US2007068650W WO2007134158A2 WO 2007134158 A2 WO2007134158 A2 WO 2007134158A2 US 2007068650 W US2007068650 W US 2007068650W WO 2007134158 A2 WO2007134158 A2 WO 2007134158A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- calcium carbonate
- granulation
- composition
- calcium
- Prior art date
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 317
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims abstract description 155
- 239000011230 binding agent Substances 0.000 title claims abstract description 63
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 47
- 230000008569 process Effects 0.000 title claims abstract description 37
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 239000008187 granular material Substances 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000005469 granulation Methods 0.000 claims abstract description 120
- 230000003179 granulation Effects 0.000 claims abstract description 120
- 239000000203 mixture Substances 0.000 claims abstract description 101
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 25
- 235000016709 nutrition Nutrition 0.000 claims abstract description 24
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 73
- 239000011575 calcium Substances 0.000 claims description 72
- 229910052791 calcium Inorganic materials 0.000 claims description 72
- 239000002552 dosage form Substances 0.000 claims description 22
- -1 sorbitan fatty acid esters Chemical class 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 15
- 229930003316 Vitamin D Natural products 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000011710 vitamin D Substances 0.000 claims description 14
- 235000019166 vitamin D Nutrition 0.000 claims description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 14
- 229940046008 vitamin d Drugs 0.000 claims description 14
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 10
- 239000000194 fatty acid Substances 0.000 claims description 10
- 229930195729 fatty acid Natural products 0.000 claims description 10
- 239000011647 vitamin D3 Substances 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 8
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 8
- 230000000717 retained effect Effects 0.000 claims description 8
- 239000000080 wetting agent Substances 0.000 claims description 8
- 206010006956 Calcium deficiency Diseases 0.000 claims description 7
- 208000013038 Hypocalcemia Diseases 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 230000000705 hypocalcaemia Effects 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 229960000913 crospovidone Drugs 0.000 claims description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 6
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 230000000181 anti-adherent effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 229910021532 Calcite Inorganic materials 0.000 claims description 4
- 239000003911 antiadherent Substances 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 229920001531 copovidone Polymers 0.000 claims description 3
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims description 3
- 229960000878 docusate sodium Drugs 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 230000035764 nutrition Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 208000015994 miscarriage Diseases 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000000995 spontaneous abortion Diseases 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 229960004274 stearic acid Drugs 0.000 claims 2
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 230000007698 birth defect Effects 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 230000009747 swallowing Effects 0.000 abstract description 5
- 239000003826 tablet Substances 0.000 description 95
- 229960005069 calcium Drugs 0.000 description 63
- 229940069978 calcium supplement Drugs 0.000 description 9
- 238000007906 compression Methods 0.000 description 8
- 230000006835 compression Effects 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940057802 caltrate Drugs 0.000 description 5
- 238000007908 dry granulation Methods 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229920003082 Povidone K 90 Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 3
- 239000001354 calcium citrate Substances 0.000 description 3
- 239000007894 caplet Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 3
- 239000011163 secondary particle Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000013337 tricalcium citrate Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 206010051315 Congenital hypoparathyroidism Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010020669 Hypermagnesaemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000020176 autoimmune hypoparathyroidism Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- DWKPZOZZBLWFJX-UHFFFAOYSA-L calcium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [Ca+2].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC DWKPZOZZBLWFJX-UHFFFAOYSA-L 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000020930 dietary requirements Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940018614 docusate calcium Drugs 0.000 description 1
- 229940018600 docusate potassium Drugs 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- CACRHRQTJDKAPJ-UHFFFAOYSA-M potassium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate Chemical compound [K+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CACRHRQTJDKAPJ-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000006078 pseudohypoparathyroidism Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention generally relates to pharmaceutical and nutritional compositions comprising calcium carbonate, processes for making such compositions and granulations useful as intermediates in such processes. More specifically, the present invention relates to compositions comprising calcium carbonate having high density and consequently reduced volume for easier swallowing.
- Calcium is an essential mineral nutrient, needed for formation of strong bones and healthy teeth, and is involved in helping blood to clot. It is also required to transmit nerve signals, and for muscle contraction, heartbeat, glandular secretion and maintenance of immune function. Calcium is found in nutritionally useful amounts in a variety of foods including milk and other dairy products, as well as in green vegetables such as spinach, in nuts and in fish with bones such as sardines. Usually, nutritional requirements for calcium are met from the diet. However, when there is insufficient calcium in the diet to meet the body's needs, supplements are needed to prevent calcium deficiency. Calcium supplements can be of value even where overall dietary intake of calcium is adequate, for example to even out day- to-day or week-to-week variations in intake and provide a "margin of error" in satisfying daily nutritional requirement.
- calcium supplementation has pharmaceutical application, for example in preventing or treating osteoporosis that is characterized by loss of normal bone density and by bone fragility.
- a chronic shortage of dietary calcium is a key factor contributing to osteoporosis development.
- administration of a calcium supplement can be therapeutically beneficial, for example to prevent or ameliorate osteoporosis-related symptoms.
- Calcium supplements may also provide benefits in reducing colonic mucosal proliferation, which in turn can lower risk of colorectal cancer; lowering systolic blood pressure in hypertensive patients; lowering serum cholesterol in some individuals, with attendant benefits such as lowering risk of stroke; ameliorating symptoms of premenstrual syndrome; and in reducing weight gain in subjects who are obese or at risk of obesity. See, for example, PDR for Nutritional Supplements, Thomson PDR, Montvale, NJ, pp. 74-79 (2001).
- Ca 2+ salts are available for oral use as calcium supplements.
- calcium carbonate and calcium phosphate have the highest elemental calcium content (about 40%).
- Other salts include calcium citrate (about 21% calcium), calcium lactate (about 13% calcium) and calcium gluconate (about 9% calcium).
- a common adult daily dose for calcium supplementation is 1200 mg, which is typically provided as two tablets each comprising 600 mg calcium, for example in the form of calcium carbonate.
- a 600 mg calcium dose is provided by about 1500 mg calcium carbonate. The need for such a large amount of calcium carbonate results in a tablet having a large volume that some consumers or patients find difficulty or feel discomfort in ingestion. This in turn can lead to reduced patient compliance.
- Calcium carbonate tablets are generally prepared by first granulating calcium carbonate powder, typically with a binder, and then compressing the resulting granulation. Calcium carbonate powders are available in two main forms, precipitated and ground. Precipitated calcium carbonate, prepared from limestone by recarbonation and precipitation of calcium carbonate from a solution, is often used and is typically preferred in tablet making for its small particle size and good compressibility. However, precipitated calcium carbonate has a high surface area and differs in its surface chemistry from other forms of calcium carbonate. These properties tend to lead to low density granulations that, on compression, produce relatively large volume dosage forms.
- U.S. Patent Application Publication No. 2005/0025811 of Levin et al. relates to highly compactable calcium carbonate granulations and methods for preparing such granulations.
- the granulations are reportedly prepared by mixing calcium carbonate powder and excipients such as maltodextrin and mineral oil in a mixer capable of creating high shear, and then drying the resulting composition, for example in a fluidized bed convection oven.
- the calcium carbonate powders used include products known to be ground calcium carbonate ⁇ e.g., OMYA-CalTM FG).
- Particle size of the calcium carbonate is said to have an effect on compactability of the granulation formed; in the broad median particle diameter range of about 0.1 to about 20 ⁇ m, a median particle diameter between about 10 and about 12 ⁇ m is said to be preferred. Combinations of larger and smaller particle size powders are also said to be useful. Tablets prepared from such granulations are said to have densities about 20% to at least about 35% greater, and to be about 20% to at least about 35% smaller in volume, than commercially available calcium supplement tablets. Specific examples of tablets containing "600 mg calcium carbonate" (600 mg calcium in the form of calcium carbonate may be intended) are reportedly about 20% smaller in volume than CALTRATE® brand 600 mg tablets.
- each tablet contains 600 mg calcium, as calcium carbonate (i.e., about 1500 mg calcium carbonate).
- the tablet also contains an unspecified amount of starch and ⁇ 2% croscarmellose sodium, magnesium stearate and titanium dioxide. It is further stated that the tablet may contain ⁇ 2% of glycerin, methylcellulose, polydextrose, polyethylene glycol, polyvinyl alcohol and talc. See http://www.caltrate.com/products/caltrate600_lbl.asp.
- calcium supplement tablets can vary from the above in composition.
- the product label for FINEST NATURALTM Calcium 500+D caplets sold by Walgreens states that each caplet contains 500 mg calcium as calcium carbonate (i.e., about 1250 mg calcium carbonate), and 125 IU (i.e., about 3 ⁇ g) vitamin D as cholecalciferol.
- Other ingredients listed are croscarmellose sodium, sodium lauryl sulfate, hydroxypropylmethylcellulose (HPMC) 3 titanium dioxide, magnesium stearate, polyethylene glycol and carnauba wax.
- a granulation can be prepared having excellent compressibility to provide a calcium carbonate dosage form such as a tablet having high density (for example, at least about 2000 mg/cm 3 ), in spite of the granulation itself having low tapped density (typically not greater than about 1000 mg/cm 3 ). Furthermore, the granulation can be prepared using ground calcium carbonate. Tablets can be prepared from such a granulation without recourse to formulation aids such as starch in amounts that would result in a calcium carbonate content of the tablets of less than about 90% by weight.
- a porosity increasing agent such as polyethylene glycol or a pharmaceutically acceptable hydrophilic surfactant
- a granulation comprising about 95% to about 99% by weight calcium carbonate, for example ground calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent.
- a granulation comprising about 95% to about 99% by weight calcium carbonate, for example ground calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of polyethylene glycol and/or one or more pharmaceutically acceptable hydrophilic surfactants.
- More particular embodiments include a granulation comprising about 97% to about 98% by weight calcium carbonate; about 1.5% to about 3% by weight binder; and about 0.05% to about 0.2% by weight of a porosity increasing agent.
- the process comprises (a) contacting a calcium carbonate powder, for example ground calcium carbonate, with water, a porosity increasing agent and a binder under sufficient shear to form a homogeneous mix, and (b) drying the mix to provide a granulation.
- the process comprises mixing the water, the porosity increasing agent and the binder to prepare a binder solution which is then contacted with the calcium carbonate powder.
- a process for preparing a pharmaceutical or nutritional composition comprising calcium carbonate.
- the process comprises preparing a calcium carbonate granulation as described above; blending the calcium carbonate granulation with one or more excipients to form a compressible blend; and compressing the blend to prepare a pharmaceutical or nutritional composition, for example in a unit dosage form such as a tablet.
- a pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients.
- Density of such a composition can be, without limitation, at least about 2000 mg/cm 3 and can be as high as about 2300 mg/cm 3 or even higher.
- the combination of high calcium carbonate load (at least about 90% by weight) and high density (at least about 2000 mg/cm ) enables a tablet composition of the invention containing about 600 mg calcium to have a volume of less than about 0.83 cm 3 .
- An illustrative pharmaceutical composition comprises at least about 95% by weight calcium carbonate and has a density of about 2100 to about 2200 mg/cm .
- the pharmaceutical composition is in tablet form and comprises about 600 mg calcium. In another embodiment, the pharmaceutical composition is in tablet form, comprises about 600 mg calcium and has a volume of less than about 0.76 cm 3 .
- a method for supplementing calcium nutrition in a subject comprising administering to the subject a composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, in an amount providing about 300 to about 1200 mg calcium per day.
- a method for treating or reducing risk of a medical disorder associated with calcium deficiency and/or hypocalcemia in a subject comprising administering to the subject a composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, in an amount providing about 300 to about 1200 mg calcium per day.
- Fig. 1 is a process flow diagram illustrating one embodiment of a manufacturing process for making a calcium supplement composition of the present invention.
- the granulations of the present invention further allow for preparation of calcium dosage forms having a lower volume, resulting from significantly higher density and/or from higher calcium carbonate loading due to lower content of excipients.
- This lower volume in turn allows for formulation of smaller dosage forms that are easier to swallow and/or the formulation of calcium carbonate with other nutrients or active ingredients without significantly varying from standard dosage form volumes.
- Lower volume also permits savings in packaging and shipping costs.
- a first embodiment of the invention provides a calcium carbonate granulation.
- a granulation typically is a free-flowing granular material comprising more or less discrete secondary particles that themselves comprise aggregates of smaller primary particles.
- a calcium carbonate granulation comprises secondary particles, illustratively of volume mean diameter about 100 to about 500 ⁇ m, which in turn comprise primary calcium carbonate particles, illustratively of volume mean diameter about 12 to about 22 ⁇ m.
- secondary particles illustratively of volume mean diameter about 100 to about 500 ⁇ m
- primary calcium carbonate particles illustratively of volume mean diameter about 12 to about 22 ⁇ m.
- Various processes are known in the art for preparing granulations, including wet granulation, dry granulation, fluidized bed granulation and extrusion granulation; in a particular embodiment, calcium carbonate granulations are prepared by a wet granulation process as described in greater detail hereinbelow.
- a granulation of the present invention comprises about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent. All weights herein are expressed on a dry basis (i.e., excluding any moisture that may be present in a composition) unless the context demands otherwise.
- any particulate form, or combination of forms, of calcium carbonate can be used, including ground calcium carbonate.
- Particle size of the calcium carbonate is not critical within a wide range, for example from about 0.1 to about 30 ⁇ m, expressed as volume mean diameter, although processing considerations (as indicated hereinbelow) may favor selection of a calcium carbonate powder having a volume mean diameter of about 10 to about 25 ⁇ m, for example about 12 to about 22 ⁇ m.
- the granulation comprises at least about 96% or at least about 97% by weight calcium carbonate.
- the granulation comprises about 97% to about 98% by weight calcium carbonate.
- Amounts of calcium carbonate as expressed herein are inclusive of natural impurities present in the calcium carbonate source. Calcium carbonate sources of high natural purity, for example conforming to pharmacopeial standards such as USP (United States Pharmacopeia), are generally preferred. In the case of ground calcium carbonate, such sources include the mineral calcite.
- the granulation comprises a porosity increasing agent, which can comprise a single material or a combination of two or more materials.
- Porosity increasing agents useful herein are hydrophilic and include polyethylene glycols of a range of molecular weights, and a variety of pharmaceutically acceptable hydrophilic surfactants, which can be nonionic or anionic.
- Suitable hydrophilic surfactants include without limitation sorbitan fatty acid esters such as sorbitan monopalmitate or sorbitan monolaurate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene 4 sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene 5 sorbitan monooleate, polyoxyethylene 20 sorbitan monooleate (polysorbate 80) or polyoxyethylene 20 sorbitan trioleate; alkyl sulfates such as sodium lauryl sulfate; sulfosuccinates such as docusate sodium, docusate potassium or docusate calcium; glyceryl fatty acid esters such as glyceryl monostearate; polyglycol fatty acid esters, more particularly polyoxyethylene fatty acid esters and propylene glycol fatty acid esters such as propylene glycol monolaurate; poloxamers such as poloxamer 188 or poloxar
- the porosity increasing agent comprises polyethylene glycol, polysorbate 80, docusate sodium, sodium lauryl sulfate or a combination thereof.
- the porosity increasing agent is present in the granulation in an amount of about 0.03% to about 3% by weight, more typically about 0.04% to about 1% or about 0.05% to about 0.5%, for example about 0.05% to about 0.2% by weight.
- any binder known in the art can be used, including povidone of any suitable K-value; copovidone; modified celluloses such as HPMC, hydroxypropylcellulose, carmellose sodium or a combination thereof, hi a preferred embodiment, the binder comprises povidone, for example povidone K-90. hi various embodiments the binder is present in the granulation in an amount of about 0.5% to about 5%, about 0.4% to about 4%, about 1% to about 3.5%, or about 1.5% to about 3%, by weight. [0041] Other ingredients can be present in the granulation if desired. [0042] The granulation should be free-flowing and is typically of a sand-like texture.
- Particle size (i.e., secondary particle size) distribution is not narrowly critical, but, illustratively, less than about 2% by weight of the granulation is retained by a 20 mesh sieve, about 30% to about 42% by weight of the granulation is retained by a 60 mesh sieve, about 55% to about 70% of the granulation is retained by a 100 mesh sieve, and at least about 80% by weight of the granulation is retained by a 200 mesh sieve. All mesh sizes herein refer to Tyler Standard sieve series, using a Tyler Ro-Tap sieve shaker for particle size analysis.
- At least about 30% by weight of the particles are larger than about 250 ⁇ m, at least about 55% by weight of the particles are larger than about 150 ⁇ m, and at least about 80% by weight of the particles are larger than about 75 ⁇ m.
- a relatively high density granulation is desirable.
- Preferred granulated calcium carbonate compositions are provided having an average tap density between about 1.1 and about 2.0 g/cm 3 .
- the most preferred granulated calcium carbonate compositions according to the invention have tap densities greater than 1.3 g/cm 3 .”
- the present invention contrary to the '811 publication, provides a granulation that typically has relatively low tapped density.
- the tapped density (1000 taps) of a granulation as described above is less than about 1100 mg/cm 3 , for example about 750 to about 1050 mg/cm 3 , more typically about 800 to about 1000 mg/cm 3 .
- This is a considerably lower density than a typical ground calcium carbonate powder used as a starting material, which can illustratively have a tapped density (1000 taps) of about 1400 to about 1700 mg/cm 3 .
- incorporation of a porosity increasing agent in the granulation in accordance with the present invention accounts for the unusually low tapped density of the granulation. Yet, in spite of the low density of the granulation, it is capable of compaction to provide a tablet having higher density than commercially available calcium carbonate tablets, as demonstrated hereinbelow. It is further believed, again without being bound by theory, that the porosity increasing agent leads to creation of channel structures in the granulation, and that drying and then compacting the granulation results in a collapsing of the channel structures to form a highly packed composite providing tablets with high density and low volume.
- the granulations of the present invention are not limited by the process used to prepare them. An illustrative process for preparing a granulation as described above is now described.
- a calcium carbonate powder for example ground calcium carbonate
- a porosity increasing agent and a binder under sufficient shear to provide a homogeneous mix.
- Suitable calcium carbonate sources for use in the process generally include any calcite form of calcium carbonate having a volume mean particle size of about 12 to about 22 ⁇ m and a bulk density of about 900 to about 1100 mg/cm 3 .
- the calcium carbonate source is a calcite form of calcium carbonate having a volume mean particle size of about 16 to about 18 ⁇ m, an overall surface energy of at least about 35 mJ/m 2 , a surface polarity of at least about 30%, and a tapped density (1000 taps) of about 1400 to about 1700 mg/cm 3 .
- Suitable porosity increasing agents and binders are as described above. Relative amounts of calcium carbonate, porosity increasing agent and binder are as set forth above; for the present process about 97 to about 98 parts by weight calcium carbonate, about 0.05 to about 0.2 parts by weight porosity increasing agent and about 1.5 to about 3 parts by weight binder will generally be found suitable.
- a suitable amount of water to provide satisfactory granulation will be readily determined by one of skill in the art by routine experimentation; typically such an amount will be about 10% to about 15%, for example about 11% to about 14%, of the weight of the calcium carbonate.
- the water, porosity increasing agent and binder are first mixed to prepare a binder solution, which is then contacted with the calcium carbonate.
- a suitable binder solution generally comprises about 10% to about 20% by weight of the binder, about 0.2% to about 1.5% (for example about 0.3% to about 1.3%) by weight of the porosity increasing agent, and about 80% to about 90% by weight water.
- a binder solution can be prepared by contacting the binder and the porosity increasing agent with water while mixing.
- the binder is introduced into a vessel with water heated to a temperature of about 25 °C to about 4O 0 C, and mixed at a mixing speed of about 2000 to about 8000 rpm until the binder is dissolved. After the binder is dissolved, the mixing speed is reduced and the porosity increasing agent is added slowly. A reduced mixing speed of about 2000 to about 3000 rpm is maintained until the porosity increasing agent is adequately dispersed.
- the water, porosity increasing agent and binder are added to the calcium carbonate under shear conditions sufficient to provide a homogeneous mix, or "wet granulation composition".
- the binder solution and calcium carbonate are contacted in a continuous high shear paddle mixer operating at an impeller speed of about 1800 to about 2000 rpm.
- the calcium carbonate is introduced into the mixer at a rate of about 1700 to about 1900 g/minute.
- the binder solution is introduced into the mixer at a rate of about 245 to about 350 g/minute.
- the amount of binder solution is controlled to give a granulation moisture level of about 11% to about 14% based on the amount of calcium carbonate used.
- the resulting wet granulation composition is dried, for example in a fluidized bed or tray dryer at a temperature of about 40°C to about 60°C to provide a granulation of the invention.
- the composition is dried to a moisture level of not greater than about 2% by weight, preferably from about 0.3% to about 1% by weight.
- the dried granulation is then optionally screened, for example using an 18 to 20 mesh screen, to remove any oversized particles.
- the granulation prepared as above comprises at least about 97% by weight calcium carbonate, about 1.5% to about 3% by weight binder and about 0.01% to about 0.2% by weight porosity increasing agent, and has a moisture content of less than about
- the granulation comprises about 97% to about
- the dry granulation comprises 97.5% ground calcium carbonate, 2.4% povidone K-90 and 0.1% polysorbate 80.
- Granulations prepared as above typically have a tapped density (1000 taps) of about 800 to about 1000 mg/cm 3 .
- FIG. 1 one embodiment of a process of the present invention for preparing a calcium granulation is illustrated schematically.
- the process generally comprises contacting water 20, a binder 40 and a porosity increasing agent 60 in a mixer 100 to prepare a binder solution 101.
- the binder solution 101 is then contacted with calcium carbonate 103 in a continuous high shear paddle mixer 200 to prepare a wet granulation composition 201.
- the wet granulation composition 201 is dried in a fluidized bed or tray dryer 300, then screened with a screen or sieve 400 to remove any oversized particles and provide the finished granulation 401.
- the resulting granulation can be used for filling capsules, or can be processed into tablets or other types of solid unit dosage forms.
- the granulation is especially useful in preparation of compressed unit dosage forms such as tablets for oral administration as nutritional supplements or medicaments.
- Granulations of the present invention in spite of having relatively low tapped density, are compressible to form high density tablets.
- a further embodiment of the invention provides a process for preparing a pharmaceutical or nutritional composition comprising calcium carbonate.
- the process comprises preparing a calcium carbonate granulation, for example as described above; blending the calcium carbonate granulation with one or more excipients to form a compressible blend; and compressing the blend to prepare a pharmaceutical or nutritional composition, for example in a unit dosage form such as a tablet.
- the total amount of such excipients and any other materials added to the blend is sufficiently small that the resulting composition, for example tablet, comprises at least about 90% by weight, for example about 90% to about 99% by weight, calcium carbonate.
- the dry granulation 401 is, in one embodiment, contacted with one or more excipients 403 including, for example, diluents or fillers, disintegrants or disintegrating agents, wetting agents, anti-adherents, glidants, lubricants, and/or other miscellaneous adjuncts such as colorants, and optionally with one or more additional nutritional or pharmaceutically active ingredients, for example vitamins such as vitamin D, in a blender 500 to form a tableting mix 501 which is then compressed into tablets with a tablet press 600.
- excipients 403 including, for example, diluents or fillers, disintegrants or disintegrating agents, wetting agents, anti-adherents, glidants, lubricants, and/or other miscellaneous adjuncts such as colorants, and optionally with one or more additional nutritional or pharmaceutically active ingredients, for example vitamins such as vitamin D, in a blender 500 to form a tableting mix 501 which is then compressed into tablets with a tablet press 600.
- Diluents such as starch or lactose are typically not required in preparing tablets according to the present invention, but small amounts, for example amounts that do not dilute calcium carbonate content of the tablets below about 90%, can be added if desired.
- One or more disintegrants can be included to assist breaking up of the tablet in the gastrointestinal tract after swallowing, and thereby accelerate dissolution to release calcium for intestinal absorption. Disintegrants can be generally be incorporated into the granulation (intragranular disintegrant) during the granulation process, or into the tableting mix prior to compression (extragranular disintegrant), or both.
- disintegrants examples include starch, sodium starch glycolate, alginic acid, guar gum, croscarmellose sodium, crospovidone, ion exchange resins and combinations thereof. Tablets can illustratively contain about 1% to about 5%, for example about 1.5% to about 4% or about 2% to about 3%, by weight in total of one or more disintegrants, for example crospovidone, sodium starch glycolate and/or croscarmellose sodium.
- One or more wetting agents can be included if desired, for example to assist in dispersion of the calcium carbonate in gastrointestinal fluid and thereby further accelerate dissolution.
- wetting agents can be the same as or different from hydrophilic surfactants used in the granulation process as porosity increasing agents.
- hydrophilic surfactants used in the granulation process as porosity increasing agents.
- sodium lauryl sulfate is a useful wetting agent.
- about 0.05% to about 0.5%, for example about 0.1% to about 0.25%, by weight of one or more wetting agents can optionally be added to the tableting mix.
- glidants Materials useful to improve flow characteristics of granulations, for example in preparing a tableting mix, are referred to as glidants.
- Suitable glidants include, for example, silicon dioxide, magnesium lauryl sulfate, magnesium aluminum silicate, magnesium oxide, talc, clays and combinations thereof. Glidants can be blended with the granulation to reduce inter-particulate friction and to eliminate problems associated with the flow of the tableting mix from larger to smaller apertures in a tablet press.
- Lubricants may also be added to reduce friction and wear during processing. Some lubricants also demonstrate anti-adherent properties that can prevent the tableting mix from sticking during the tablet making process.
- suitable lubricants include magnesium stearate, talc, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, high melting point waxes and combinations thereof.
- Tablets can illustratively contain about 0.1% to about 2%, for example about 0.25% to about 1%, by weight in total of one or more glidants, lubricants and/or anti- adherents.
- the relatively low density granulations of the invention can be compressed to form high density tablets having a high loading (at least about 90% by weight) of calcium carbonate.
- a compression force should be applied that is sufficient, in the particular tablet press fitted with the particular tablet dies to be used, to compress the tableting mix into a tablet having a density of at least about 2000 mg/cm 3 .
- Tablet density can be as high as about 2300 mg/cm 3 or even higher; however, it is generally desirable to avoid excessively high tablet densities as these can lead to difficulties in disintegration and dissolution.
- a compression force is selected to provide a tablet density of about 2100 to about 2200 mg/cm 3 .
- Yet another embodiment of the invention provides a pharmaceutical or nutritional composition
- a pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, including about 0.5% to about 5% by weight of binder present in the granulation before blending.
- Density of such a composition can be, without limitation, at least about 2000 mg/cm and can be as high as about 2300 mg/cm or even higher.
- the amount by weight of porosity increasing agent in a pharmaceutical or nutritional composition includes, for convenience, not only the amount added in the granulation process as described above, but also any amount of polyethylene glycol or hydrophilic surfactant optionally added as an excipient (e.g., as a wetting agent) to the tableting mix prior to compression.
- the composition is a unit dosage form, in particular a compressed unit dosage form such as a tablet.
- Tablets herein embrace compressed dosage forms of any shape, including those elongated forms referred to in the art as “caplets”.
- a tablet of the invention can comprise about 92% to about 98%, for example about 94% to about 97%, by weight calcium carbonate.
- An illustrative pharmaceutical composition comprises at least about 95% by weight calcium carbonate and has a density of about 2100 to about 2200 mg/cm .
- Tablets can be made in any desired size and shape but it is preferred that tablet volume is no greater than about 0.83 cm 3 . It can be calculated that a tablet having at least about 90% by weight calcium carbonate, and having a density of at least about 2000 mg/cm 3 and a volume no greater than about 0.83 cm , can contain 600 mg calcium.
- Unit dosage forms of the invention illustratively contain about 300 to about 600 mg calcium, in the form of calcium carbonate.
- the pharmaceutical or nutritional composition is in tablet form and comprises about 600 mg calcium.
- the combination of high calcium carbonate load (at least about 90% by weight) and high density (at least about 2000 mg/cm 3 ) enables a tablet composition of the invention containing about 600 mg calcium to have a volume of less than about 0.83 cm .
- the volume of such a tablet in some embodiments, is about 0.67 to about 0.83 cm 3 , for example about 0.7 to about 0.8 cm 3 or about 0.72 to about 0.77 cm 3 .
- Lower dose tablets containing for example about 550 mg, about 500 mg, about 450 mg, about 400 mg, about 350 mg or about 300 mg calcium, can have proportionally lower volume.
- CALTRATE® 600 mg calcium tablets of Wyeth have been determined to have an average weight of about 1850 mg; based on a calcium carbonate amount of about 1500 mg (equivalent to 600 mg calcium) and assuming a moisture content of about 0.5%, the calcium carbonate loading of these tablets is calculated to be about 81.5% by weight. These tablets have further been determined to have a density of about 1950 mg/cm 3 and an average volume of about 0.95 cm 3 .
- the pharmaceutical or nutritional composition is in tablet form, comprises about 600 mg calcium and has a volume of less than about 0.76 cm 3 , for example about 0.72 to about 0.76 cm 3 .
- the present invention allows for the preparation of tablets comprising about 300 to about 600 mg calcium in the form of calcium carbonate, and having a volume that is about 15% to about 30% smaller than conventional calcium carbonate tablets such as CALTRATE® tablets.
- Tablets prepared from the granulations of the present invention illustratively exhibit a breaking force of about 25 to about 30 Kp, a tablet density of from about 2100 to about 2200 mg/cm 3 , a friability of about 0.1% to about 0.4%, and a disintegration time of about 4 to about 8 minutes, all as measured using tests standard in the art.
- a 600 mg calcium tablet of the invention illustratively has a thickness of about 0.26 to about 0.27 inches (about 6.7 to about 6.9 mm) and a tablet weight of about 1540 to about 1640 mg.
- Pharmaceutical and nutritional compositions of the invention optionally further comprise one or more additional pharmaceutically or nutritionally active ingredients. In some embodiments, such additional ingredients comprise one or more vitamins or vitamin sources.
- a composition of the invention comprises a vitamin D source such as vitamin D 2 (ergocalciferol) or vitamin D 3 (cholecalciferol), which can enhance intestinal absorption of calcium.
- a vitamin D source such as vitamin D 2 (ergocalciferol) or vitamin D 3 (cholecalciferol)
- additional ingredients can be added at any stage in the process of preparing a compositions including the granulation process, but typically it will be found most convenient to add such ingredients after granulation, when preparing a blend for example as a tableting mix.
- vitamins such as vitamin D are used in very small quantities and it can be advantageous to add them to the tableting mix in the form of dilute solutions in a suitable solvent, for example vegetable oil, polysorbate 80 or propylene glycol in the case of vitamin D 3 , or as a powder in mixture with a solid diluent such as sucrose, starch and/or dextrin.
- a suitable solvent for example vegetable oil, polysorbate 80 or propylene glycol in the case of vitamin D 3
- a solid diluent such as sucrose, starch and/or dextrin.
- a calcium carbonate tablet of the invention for example as described in detail above, comprising about 300 to about 600 mg calcium in the form of calcium carbonate, further comprises a vitamin D source, illustratively vitamin D 3 , in an amount of about 1 to about 30 ⁇ g, for example about 2.5 to about 25 ⁇ g, about 3 to about 20 ⁇ g or about 5 to about 15 ⁇ g per tablet, wherein 1 ⁇ g is equivalent to 40 IU vitamin D.
- a vitamin D source illustratively vitamin D 3 , in an amount of about 1 to about 30 ⁇ g, for example about 2.5 to about 25 ⁇ g, about 3 to about 20 ⁇ g or about 5 to about 15 ⁇ g per tablet, wherein 1 ⁇ g is equivalent to 40 IU vitamin D.
- a nutritional composition of the invention is useful in a method for supplementing calcium nutrition in a subject, the method comprising administering to the subject such a composition, for example one or more tablets, in an amount providing about 300 to about 1500 mg calcium per day, for example about 600 to about 1200 mg calcium per day.
- Calcium supplementation is advantageous not only where the diet is low in calcium, but also where hypocalcemia is caused or exacerbated by other factors.
- calcium absorption into the circulatory system can be decreased by low levels of parathyroid hormone secretion (hypoparathyroidism), e.g., post-operative, autoimmune or congenital hypoparathyroidism, or reduced response to parathyroid hormone secretion (pseudohypoparathyroidism); magnesium depletion or extreme hypermagnesemia; or vitamin D deficiency.
- Calcium loss from the circulatory system can be increased, by hyperphosphatemia, for example associated with renal failure, rhabdomyolysis, tumor lysis or phosphate administration; acute pancreatitis; chelating agents such as citrate, lactate or EDTA; or osteoblastic metastases, for example in prostate or breast cancer.
- a composition of the invention is administered concomitantly with a drug such as a steroid, PPI antiviral or chemotherapeutic that reduces calcium absorption or increases calcium loss, the composition being administered in an amount effective to at least partly offset the reduced calcium absorption or increased calcium loss.
- a pharmaceutical composition of the invention is useful in a method for treating or reducing risk of a medical disorder precipitated or aggravated by calcium deficiency and/or hypocalcemia in a subject, the method comprising administering to the subject such a composition, for example one or more tablets, in an amount providing about 300 to about 1500 mg calcium per day, for example about 600 to about 1200 mg calcium per day.
- Examples of medical disorders that can be precipitated or aggravated by calcium deficiency, particularly chronic calcium deficiency, and/or hypocalcemia include without restriction bone disorders including osteoporosis, osteomalacia and rickets; joint disorders; periodontal disorders; prostate or colorectal cancer; hypertension, for example systolic hypertension; kidney stones (due, for example, to excess calcium in urine associated with depletion of bone calcium); hyperlipidemia; cardiovascular and/or hemorrhagic disorders including stroke; menstrual disorders including premenstrual syndrome; miscarriage; birth, particularly heart, defects; obesity; sleep disorders; and mental, for example depressive, disorders.
- a composition of the invention is administered concomitantly with a drug that treats or alleviates a medical disorder precipitated or aggravated by calcium deficiency and/or hypocalcemia.
- This example describes the preparation of a dry granulation comprising ground calcium carbonate, a binder and a porosity increasing agent.
- the granulation was prepared in general accordance with the process illustrated in Fig. 1 and described above.
- the experiment was begun by preparing a binder solution in a stainless steel mixer.
- the solution was prepared by adding heated water (263.75 g/min at 3O 0 C to 35 0 C) to the vessel followed by binder (povidone K-90, 44.3 g/min).
- the binder was mixed at an impeller speed of about 7200 rpm until dissolved. Once the binder was dissolved, the mixing speed was reduced to about 2200 rpm and the porosity increasing agent (polysorbate 80, 1.85 g/min) was added slowly and mixed until dispersed. Mixing was continued for approximately 10 minutes to ensure that the porosity increasing agent was adequately dispersed.
- the resulting binder solution comprised 85.1% water, 14.3% binder and 0.6% porosity increasing agent.
- the binder solution and calcium carbonate were then introduced into a continuous high shear paddle mixer (Turbulizer, Model TCS, Size 8 commercially available from Hosakawa Bepex, Minneapolis, MN) to produce a calcium carbonate granulation.
- the ground calcium carbonate (CalcipureTM calcium carbonate HD 212 USP/Ph. Eur., Code 9-4863) was fed into the continuous high shear paddle mixer at a controlled rate (1800 g/min) using a powder feeder (AccuRate Model No. 580-354600).
- the binder solution was introduced to the continuous high shear paddle mixer at a controlled rate (309.9 g/min) by means of a progressing cavity pump and spray nozzle.
- the mixer was operated continuously with an impeller speed of about 1900 rpm until the desired amount of granulation was produced.
- the material exiting the continuous high shear paddle mixer was continually monitored visually and evaluated for texture and moisture.
- the finished granulation was dried at approximately 45 0 C to a moisture level of no more than 2% by weight.
- the resulting dried material was passed through an oscillator using a 20 mesh screen to remove any oversized particles.
- the final dry granulation contained 97.5% ground calcium carbonate, 2.4% binder and 0.1% porosity increasing agent.
- the granulation exhibited a typical tapped density (1000 taps) of 0.9 g/ml.
- the granulation had a typical particle size (determined using a Tyler Ro-tap sieve shaker) as shown in Table 1. Table 1
- This example describes the preparation of tablets comprising 600 mg calcium using the granulation described in Example 1.
- the tablets were prepared by blending the calcium carbonate granulation prepared in Example 1 with crospovidone (20.6 mg/tablet), sodium starch glycolate (20.6 mg/tablet), magnesium stearate (7.91 mg/tablet) and sodium lauryl sulfate (3.17 mg/tablet) in a P-K twin shell blender.
- the total theoretical tablet weight was 1590.7 mg comprising 96.71% of the calcium carbonate granulation, 1.29% crospovidone, 1.29% sodium starch glycolate, 0.5% magnesium stearate and 0.2% sodium lauryl sulfate.
- Tablets were produced from the blend using 0.3125 inch X 0.7500 inch (approximately 7.5 mm X 18 mm) modified capsule shaped tooling at a compression force of approximately 42 kN.
- the tablets exhibited excellent tablet characteristics including high breaking force, low friability, low volume, high density, short disintegration time and fast dissolution rate, as shown in Table 2.
- This example describes the preparation of tablets comprising 600 mg calcium with vitamin D 3 using the granulation described in Example 1.
- the tablets were prepared by blending the calcium carbonate granulation produced in Example 1 (1538.54 mg/tablet) with vitamin D 3 (1.11 mg/tablet of a vitamin D 3 powder containing 400 IU/mg, i.e., 11 ⁇ g vitamin D 3 /tablet), croscarmellose sodium (39.56 mg/ tablet), stearic acid (3.97 mg/tablet), magnesium stearate (3.97 mg/tablet) and sodium lauryl sulfate (1.59 mg/tablet) in a P-K twin shell blender.
- the total theoretical tablet weight was 1588.7 mg, comprising 96.84% of the calcium carbonate granulation, 0.07% vitamin D 3 solution, 2.49% croscarmellose sodium, 0.25% stearic acid, 0.25% magnesium stearate and 0.1% sodium lauryl sulfate.
- Tablets were produced from the blend using 0.3125 inch X 0.7500 inch (approximately 7.5 mm X 18 mm) modified capsule shaped tooling at a compression force of approximately 42 kN.
- the tablets exhibited excellent tablet characteristics including high breaking force, low friability, low volume, high density, short disintegration time and fast dissolution rate, as shown in Table 3.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Compositions comprising calcium carbonate and processes for making such compositions are provided. The invention provides a granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent. A pharmaceutical or nutritional composition prepared from such a granulation comprises about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients. The composition provides a smaller tablet than conventional calcium carbonate compositions, for improved ease of swallowing.
Description
CALCIUM COMPOSITIONS
[0001] This application claims the benefit of U.S. provisional application Serial No. 60/800,178, filed on May 12, 2006, the entire disclosure of which is incorporated herein by reference.
FIELD OF THE INVENTION
[0002] The present invention generally relates to pharmaceutical and nutritional compositions comprising calcium carbonate, processes for making such compositions and granulations useful as intermediates in such processes. More specifically, the present invention relates to compositions comprising calcium carbonate having high density and consequently reduced volume for easier swallowing.
BACKGROUND OF THE INVENTION
[0003] Calcium is an essential mineral nutrient, needed for formation of strong bones and healthy teeth, and is involved in helping blood to clot. It is also required to transmit nerve signals, and for muscle contraction, heartbeat, glandular secretion and maintenance of immune function. Calcium is found in nutritionally useful amounts in a variety of foods including milk and other dairy products, as well as in green vegetables such as spinach, in nuts and in fish with bones such as sardines. Usually, nutritional requirements for calcium are met from the diet. However, when there is insufficient calcium in the diet to meet the body's needs, supplements are needed to prevent calcium deficiency. Calcium supplements can be of value even where overall dietary intake of calcium is adequate, for example to even out day- to-day or week-to-week variations in intake and provide a "margin of error" in satisfying daily nutritional requirement.
[0004] In addition to helping meet dietary requirements, calcium supplementation has pharmaceutical application, for example in preventing or treating osteoporosis that is characterized by loss of normal bone density and by bone fragility. Among various factors, a chronic shortage of dietary calcium is a key factor contributing to osteoporosis development. Thus administration of a calcium supplement can be therapeutically beneficial, for example to prevent or ameliorate osteoporosis-related symptoms. [0005] Calcium supplements may also provide benefits in reducing colonic mucosal
proliferation, which in turn can lower risk of colorectal cancer; lowering systolic blood pressure in hypertensive patients; lowering serum cholesterol in some individuals, with attendant benefits such as lowering risk of stroke; ameliorating symptoms of premenstrual syndrome; and in reducing weight gain in subjects who are obese or at risk of obesity. See, for example, PDR for Nutritional Supplements, Thomson PDR, Montvale, NJ, pp. 74-79 (2001).
[0006] Absorption of calcium in the small intestine depends on the action of 1,25- dihydroxycholecalciferol, a metabolite of vitamin D. For this reason, some calcium supplements include a source of vitamin D such as vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol).
[0007] Numerous calcium (Ca2+) salts are available for oral use as calcium supplements. Among salts that can effectively be used for calcium supplementation, calcium carbonate and calcium phosphate have the highest elemental calcium content (about 40%). Other salts include calcium citrate (about 21% calcium), calcium lactate (about 13% calcium) and calcium gluconate (about 9% calcium). A common adult daily dose for calcium supplementation is 1200 mg, which is typically provided as two tablets each comprising 600 mg calcium, for example in the form of calcium carbonate. A 600 mg calcium dose is provided by about 1500 mg calcium carbonate. The need for such a large amount of calcium carbonate results in a tablet having a large volume that some consumers or patients find difficulty or feel discomfort in ingestion. This in turn can lead to reduced patient compliance. Even a 300 mg calcium tablet (containing about 750 mg calcium carbonate) is uncomfortably large for some people. It is noteworthy that elderly people, one of the subpopulations that are most prone to osteoporosis, often have especial difficulty in swallowing large dosage forms. Therefore, there is a need for a smaller volume calcium composition that is easier to swallow. [0008] Calcium carbonate tablets are generally prepared by first granulating calcium carbonate powder, typically with a binder, and then compressing the resulting granulation. Calcium carbonate powders are available in two main forms, precipitated and ground. Precipitated calcium carbonate, prepared from limestone by recarbonation and precipitation of calcium carbonate from a solution, is often used and is typically preferred in tablet making for its small particle size and good compressibility. However, precipitated calcium carbonate has
a high surface area and differs in its surface chemistry from other forms of calcium carbonate. These properties tend to lead to low density granulations that, on compression, produce relatively large volume dosage forms.
[0009] Efforts to develop a lower volume calcium supplement dosage form have included use of alternative Ca2+ salts such as calcium citrate. For example, U.S. Patent No. 6,818,228 to Walsdorf et al. mentions a dietary supplement comprising a high bulk density form of calcium citrate.
[0010] Ground calcium carbonate tends to have higher bulk density than precipitated calcium carbonate and is sometimes described in the art as "heavy calcium carbonate." However, it poses its own challenges when used to prepare tablets. Haines-Nutt, J. Pharm. Pharmac. 28:468-470 (1976) reported that compacts made up from heavy calcium carbonate are weaker and more friable than similar compacts prepared from heavy magnesium carbonate, and speculated that this might result from absence of water of crystallization in calcium carbonate.
[0011] U.S. Patent Application Publication No. 2005/0025811 of Levin et al. relates to highly compactable calcium carbonate granulations and methods for preparing such granulations. The granulations are reportedly prepared by mixing calcium carbonate powder and excipients such as maltodextrin and mineral oil in a mixer capable of creating high shear, and then drying the resulting composition, for example in a fluidized bed convection oven. The calcium carbonate powders used include products known to be ground calcium carbonate {e.g., OMYA-Cal™ FG). Particle size of the calcium carbonate is said to have an effect on compactability of the granulation formed; in the broad median particle diameter range of about 0.1 to about 20 μm, a median particle diameter between about 10 and about 12 μm is said to be preferred. Combinations of larger and smaller particle size powders are also said to be useful. Tablets prepared from such granulations are said to have densities about 20% to at least about 35% greater, and to be about 20% to at least about 35% smaller in volume, than commercially available calcium supplement tablets. Specific examples of tablets containing "600 mg calcium carbonate" (600 mg calcium in the form of calcium carbonate may be intended) are reportedly about 20% smaller in volume than CALTRATE® brand 600 mg tablets.
[0012] Product labeling for CALTRATE® 600 of Wyeth makes clear that each tablet contains 600 mg calcium, as calcium carbonate (i.e., about 1500 mg calcium carbonate). The tablet also contains an unspecified amount of starch and <2% croscarmellose sodium, magnesium stearate and titanium dioxide. It is further stated that the tablet may contain <2% of glycerin, methylcellulose, polydextrose, polyethylene glycol, polyvinyl alcohol and talc. See http://www.caltrate.com/products/caltrate600_lbl.asp.
[0013] Other commercially available calcium supplement tablets can vary from the above in composition. For example, the product label for FINEST NATURAL™ Calcium 500+D caplets sold by Walgreens states that each caplet contains 500 mg calcium as calcium carbonate (i.e., about 1250 mg calcium carbonate), and 125 IU (i.e., about 3 μg) vitamin D as cholecalciferol. Other ingredients listed are croscarmellose sodium, sodium lauryl sulfate, hydroxypropylmethylcellulose (HPMC)3 titanium dioxide, magnesium stearate, polyethylene glycol and carnauba wax.
[0014] There remains a need in the art for alternative calcium carbonate dosage forms having low volume to improve ease of swallowing, yet having acceptably low friability coupled with rapid disintegration and dissolution upon ingestion, and methods to prepare such dosage forms.
SUMMARY OF THE INVENTION
[0015] It has now been found that by addition of a small amount of a porosity increasing agent such as polyethylene glycol or a pharmaceutically acceptable hydrophilic surfactant to calcium carbonate powder, a granulation can be prepared having excellent compressibility to provide a calcium carbonate dosage form such as a tablet having high density (for example, at least about 2000 mg/cm3), in spite of the granulation itself having low tapped density (typically not greater than about 1000 mg/cm3). Furthermore, the granulation can be prepared using ground calcium carbonate. Tablets can be prepared from such a granulation without recourse to formulation aids such as starch in amounts that would result in a calcium carbonate content of the tablets of less than about 90% by weight.
[0016] Accordingly, there is now provided a granulation comprising about 95% to about 99% by weight calcium carbonate, for example ground calcium carbonate, about 0.5% to
about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent.
[0017] Without being bound by theory, it is believed that inclusion of polyethylene glycol or a hydrophilic surfactant enhances compressibility by increasing porosity of the granulation; however, it is not ruled out that other mechanisms could be involved. Thus in one embodiment there is provided a granulation comprising about 95% to about 99% by weight calcium carbonate, for example ground calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of polyethylene glycol and/or one or more pharmaceutically acceptable hydrophilic surfactants.
[0018] More particular embodiments include a granulation comprising about 97% to about 98% by weight calcium carbonate; about 1.5% to about 3% by weight binder; and about 0.05% to about 0.2% by weight of a porosity increasing agent.
[0019] There is also provided a process for preparing a calcium carbonate granulation as described above. The process comprises (a) contacting a calcium carbonate powder, for example ground calcium carbonate, with water, a porosity increasing agent and a binder under sufficient shear to form a homogeneous mix, and (b) drying the mix to provide a granulation. [0020] In one embodiment, the process comprises mixing the water, the porosity increasing agent and the binder to prepare a binder solution which is then contacted with the calcium carbonate powder.
[0021] There is further provided a process for preparing a pharmaceutical or nutritional composition comprising calcium carbonate. The process comprises preparing a calcium carbonate granulation as described above; blending the calcium carbonate granulation with one or more excipients to form a compressible blend; and compressing the blend to prepare a pharmaceutical or nutritional composition, for example in a unit dosage form such as a tablet. [0022] There is still further provided a pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients. Density of such a composition can be, without limitation, at least about 2000 mg/cm3 and can be as high as about 2300 mg/cm3 or even higher. The combination of high calcium carbonate load (at least about 90% by weight) and high density (at least about 2000
mg/cm ) enables a tablet composition of the invention containing about 600 mg calcium to have a volume of less than about 0.83 cm3.
[0023] An illustrative pharmaceutical composition comprises at least about 95% by weight calcium carbonate and has a density of about 2100 to about 2200 mg/cm .
[0024] In one embodiment, the pharmaceutical composition is in tablet form and comprises about 600 mg calcium. In another embodiment, the pharmaceutical composition is in tablet form, comprises about 600 mg calcium and has a volume of less than about 0.76 cm3.
[0025] There is still further provided a method for supplementing calcium nutrition in a subject, comprising administering to the subject a composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, in an amount providing about 300 to about 1200 mg calcium per day.
[0026] There is still further provided a method for treating or reducing risk of a medical disorder associated with calcium deficiency and/or hypocalcemia in a subject, comprising administering to the subject a composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, in an amount providing about 300 to about 1200 mg calcium per day.
[0027] These and other embodiments are more fully described in the detailed description that follows.
BRIEF DESCRIPTION OF THE DRAWING
[0028] The drawing described herein is for illustration purposes only and is not intended to limit the scope of the present disclosure in any way.
[0029] Fig. 1 is a process flow diagram illustrating one embodiment of a manufacturing process for making a calcium supplement composition of the present invention. [0030] It should be understood that throughout the drawing, corresponding reference numerals indicate like or corresponding parts and features.
DETAILED DESCRIPTION
[0031] The folio whig description is merely exemplary in nature and is not intended to limit the present disclosure, application, or uses.
[0032] In accordance with the present invention, improved processes for preparing calcium carbonate granulations have been discovered that permit using ground calcium carbonate. Without being bound by a particular theory, it has been discovered that addition of a porosity increasing agent to ground calcium carbonate, for example addition to a binder solution used with ground calcium carbonate, results in granulations having increased granule porosity and better compactability as compared to conventional calcium carbonate granulations. The granulations of the present invention further allow for preparation of calcium dosage forms having a lower volume, resulting from significantly higher density and/or from higher calcium carbonate loading due to lower content of excipients. This lower volume in turn allows for formulation of smaller dosage forms that are easier to swallow and/or the formulation of calcium carbonate with other nutrients or active ingredients without significantly varying from standard dosage form volumes. Lower volume also permits savings in packaging and shipping costs.
[0033] Importantly, although compressed dosage forms such as tablets prepared from the present granulations typically have high density (for example at least about 2000 mg/cm3), it has further been discovered that these dosage forms exhibit acceptably low friability, and have excellent disintegration and dissolution properties, as illustrated in the Examples herein. [0034] A first embodiment of the invention provides a calcium carbonate granulation. The term "granulation" herein, when applied to a composition as opposed to a process step, refers to an intermediate useful in preparing a compressed dosage form such as a tablet. A granulation typically is a free-flowing granular material comprising more or less discrete secondary particles that themselves comprise aggregates of smaller primary particles. Thus a calcium carbonate granulation comprises secondary particles, illustratively of volume mean diameter about 100 to about 500 μm, which in turn comprise primary calcium carbonate particles, illustratively of volume mean diameter about 12 to about 22 μm. Various processes are known in the art for preparing granulations, including wet granulation, dry granulation, fluidized bed granulation and extrusion granulation; in a particular embodiment, calcium carbonate granulations are prepared by a wet granulation process as described in greater detail hereinbelow. [0035] As indicated above, a granulation of the present invention comprises about 95% to
about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent. All weights herein are expressed on a dry basis (i.e., excluding any moisture that may be present in a composition) unless the context demands otherwise.
[0036] Any particulate form, or combination of forms, of calcium carbonate can be used, including ground calcium carbonate. Particle size of the calcium carbonate is not critical within a wide range, for example from about 0.1 to about 30 μm, expressed as volume mean diameter, although processing considerations (as indicated hereinbelow) may favor selection of a calcium carbonate powder having a volume mean diameter of about 10 to about 25 μm, for example about 12 to about 22 μm. In various embodiments, the granulation comprises at least about 96% or at least about 97% by weight calcium carbonate. In a particular embodiment, the granulation comprises about 97% to about 98% by weight calcium carbonate. Amounts of calcium carbonate as expressed herein are inclusive of natural impurities present in the calcium carbonate source. Calcium carbonate sources of high natural purity, for example conforming to pharmacopeial standards such as USP (United States Pharmacopeia), are generally preferred. In the case of ground calcium carbonate, such sources include the mineral calcite.
[0037] Importantly according to the present invention, the granulation comprises a porosity increasing agent, which can comprise a single material or a combination of two or more materials. Porosity increasing agents useful herein are hydrophilic and include polyethylene glycols of a range of molecular weights, and a variety of pharmaceutically acceptable hydrophilic surfactants, which can be nonionic or anionic. Suitable hydrophilic surfactants include without limitation sorbitan fatty acid esters such as sorbitan monopalmitate or sorbitan monolaurate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene 4 sorbitan monostearate, polyoxyethylene 20 sorbitan tristearate, polyoxyethylene 5 sorbitan monooleate, polyoxyethylene 20 sorbitan monooleate (polysorbate 80) or polyoxyethylene 20 sorbitan trioleate; alkyl sulfates such as sodium lauryl sulfate; sulfosuccinates such as docusate sodium, docusate potassium or docusate calcium; glyceryl fatty acid esters such as glyceryl monostearate; polyglycol fatty acid esters, more particularly polyoxyethylene fatty acid esters and propylene glycol fatty acid esters such as
propylene glycol monolaurate; poloxamers such as poloxamer 188 or poloxarner 407; polyoxyethylene castor oil derivatives and combinations thereof.
[0038] In a preferred embodiment the porosity increasing agent comprises polyethylene glycol, polysorbate 80, docusate sodium, sodium lauryl sulfate or a combination thereof. [0039] The porosity increasing agent is present in the granulation in an amount of about 0.03% to about 3% by weight, more typically about 0.04% to about 1% or about 0.05% to about 0.5%, for example about 0.05% to about 0.2% by weight.
[0040] Any binder known in the art can be used, including povidone of any suitable K-value; copovidone; modified celluloses such as HPMC, hydroxypropylcellulose, carmellose sodium or a combination thereof, hi a preferred embodiment, the binder comprises povidone, for example povidone K-90. hi various embodiments the binder is present in the granulation in an amount of about 0.5% to about 5%, about 0.4% to about 4%, about 1% to about 3.5%, or about 1.5% to about 3%, by weight. [0041] Other ingredients can be present in the granulation if desired. [0042] The granulation should be free-flowing and is typically of a sand-like texture. Particle size (i.e., secondary particle size) distribution is not narrowly critical, but, illustratively, less than about 2% by weight of the granulation is retained by a 20 mesh sieve, about 30% to about 42% by weight of the granulation is retained by a 60 mesh sieve, about 55% to about 70% of the granulation is retained by a 100 mesh sieve, and at least about 80% by weight of the granulation is retained by a 200 mesh sieve. All mesh sizes herein refer to Tyler Standard sieve series, using a Tyler Ro-Tap sieve shaker for particle size analysis. Put another way, in one embodiment at least about 30% by weight of the particles are larger than about 250 μm, at least about 55% by weight of the particles are larger than about 150 μm, and at least about 80% by weight of the particles are larger than about 75 μm. [0043] To be useful in preparing a high density tablet, it is generally suggested in the art that a relatively high density granulation is desirable. For example, according to above-cited U.S. Patent Application Publication No. 2005/0025811 ("the '811 publication"), at paragraph 0015 thereof: "Preferred granulated calcium carbonate compositions are provided having an average tap density between about 1.1 and about 2.0 g/cm3. The most preferred granulated
calcium carbonate compositions according to the invention have tap densities greater than 1.3 g/cm3."
[0044] The present invention, contrary to the '811 publication, provides a granulation that typically has relatively low tapped density. In one embodiment, the tapped density (1000 taps) of a granulation as described above is less than about 1100 mg/cm3, for example about 750 to about 1050 mg/cm3, more typically about 800 to about 1000 mg/cm3. This is a considerably lower density than a typical ground calcium carbonate powder used as a starting material, which can illustratively have a tapped density (1000 taps) of about 1400 to about 1700 mg/cm3. It is believed, again without being bound by theory, that incorporation of a porosity increasing agent in the granulation in accordance with the present invention accounts for the unusually low tapped density of the granulation. Yet, in spite of the low density of the granulation, it is capable of compaction to provide a tablet having higher density than commercially available calcium carbonate tablets, as demonstrated hereinbelow. It is further believed, again without being bound by theory, that the porosity increasing agent leads to creation of channel structures in the granulation, and that drying and then compacting the granulation results in a collapsing of the channel structures to form a highly packed composite providing tablets with high density and low volume.
[0045] The granulations of the present invention are not limited by the process used to prepare them. An illustrative process for preparing a granulation as described above is now described.
[0046] In the illustrative process, a calcium carbonate powder, for example ground calcium carbonate, is first contacted with water, a porosity increasing agent and a binder, under sufficient shear to provide a homogeneous mix. Suitable calcium carbonate sources for use in the process generally include any calcite form of calcium carbonate having a volume mean particle size of about 12 to about 22 μm and a bulk density of about 900 to about 1100 mg/cm3. In a preferred embodiment, the calcium carbonate source is a calcite form of calcium carbonate having a volume mean particle size of about 16 to about 18 μm, an overall surface energy of at least about 35 mJ/m2, a surface polarity of at least about 30%, and a tapped density (1000 taps) of about 1400 to about 1700 mg/cm3. Suitable porosity increasing agents and binders are as described above. Relative amounts of calcium carbonate, porosity
increasing agent and binder are as set forth above; for the present process about 97 to about 98 parts by weight calcium carbonate, about 0.05 to about 0.2 parts by weight porosity increasing agent and about 1.5 to about 3 parts by weight binder will generally be found suitable. A suitable amount of water to provide satisfactory granulation will be readily determined by one of skill in the art by routine experimentation; typically such an amount will be about 10% to about 15%, for example about 11% to about 14%, of the weight of the calcium carbonate. [0047] In a particular embodiment, the water, porosity increasing agent and binder are first mixed to prepare a binder solution, which is then contacted with the calcium carbonate. A suitable binder solution generally comprises about 10% to about 20% by weight of the binder, about 0.2% to about 1.5% (for example about 0.3% to about 1.3%) by weight of the porosity increasing agent, and about 80% to about 90% by weight water. [0048] A binder solution can be prepared by contacting the binder and the porosity increasing agent with water while mixing. Illustratively, the binder is introduced into a vessel with water heated to a temperature of about 25 °C to about 4O0C, and mixed at a mixing speed of about 2000 to about 8000 rpm until the binder is dissolved. After the binder is dissolved, the mixing speed is reduced and the porosity increasing agent is added slowly. A reduced mixing speed of about 2000 to about 3000 rpm is maintained until the porosity increasing agent is adequately dispersed.
[0049] The water, porosity increasing agent and binder (or, in the particular embodiment described above, the solution containing the binder and porosity increasing agent) are added to the calcium carbonate under shear conditions sufficient to provide a homogeneous mix, or "wet granulation composition". In a particular embodiment, the binder solution and calcium carbonate are contacted in a continuous high shear paddle mixer operating at an impeller speed of about 1800 to about 2000 rpm. The calcium carbonate is introduced into the mixer at a rate of about 1700 to about 1900 g/minute. The binder solution is introduced into the mixer at a rate of about 245 to about 350 g/minute. The amount of binder solution is controlled to give a granulation moisture level of about 11% to about 14% based on the amount of calcium carbonate used.
[0050] The resulting wet granulation composition is dried, for example in a fluidized bed or tray dryer at a temperature of about 40°C to about 60°C to provide a granulation of the
invention. The composition is dried to a moisture level of not greater than about 2% by weight, preferably from about 0.3% to about 1% by weight. The dried granulation is then optionally screened, for example using an 18 to 20 mesh screen, to remove any oversized particles.
[0051] After drying, the granulation prepared as above comprises at least about 97% by weight calcium carbonate, about 1.5% to about 3% by weight binder and about 0.01% to about 0.2% by weight porosity increasing agent, and has a moisture content of less than about
2% by weight, hi a particular embodiment, the granulation comprises about 97% to about
98% by weight calcium carbonate, about 1.8% to about 2.9% by weight binder and about
0.05% to about 0.15% by weight porosity increasing agent, and has a moisture content of about 0.3% to about 1% by weight after drying. In a further particular embodiment, the dry granulation comprises 97.5% ground calcium carbonate, 2.4% povidone K-90 and 0.1% polysorbate 80.
[0052] Granulations prepared as above typically have a tapped density (1000 taps) of about 800 to about 1000 mg/cm3.
[0053] Referring now to Fig. 1, one embodiment of a process of the present invention for preparing a calcium granulation is illustrated schematically. The process generally comprises contacting water 20, a binder 40 and a porosity increasing agent 60 in a mixer 100 to prepare a binder solution 101. The binder solution 101 is then contacted with calcium carbonate 103 in a continuous high shear paddle mixer 200 to prepare a wet granulation composition 201.
The wet granulation composition 201 is dried in a fluidized bed or tray dryer 300, then screened with a screen or sieve 400 to remove any oversized particles and provide the finished granulation 401.
[0054] The resulting granulation can be used for filling capsules, or can be processed into tablets or other types of solid unit dosage forms. The granulation is especially useful in preparation of compressed unit dosage forms such as tablets for oral administration as nutritional supplements or medicaments. Granulations of the present invention, in spite of having relatively low tapped density, are compressible to form high density tablets.
[0055] Thus, a further embodiment of the invention provides a process for preparing a pharmaceutical or nutritional composition comprising calcium carbonate. The process
comprises preparing a calcium carbonate granulation, for example as described above; blending the calcium carbonate granulation with one or more excipients to form a compressible blend; and compressing the blend to prepare a pharmaceutical or nutritional composition, for example in a unit dosage form such as a tablet. In one embodiment, the total amount of such excipients and any other materials added to the blend is sufficiently small that the resulting composition, for example tablet, comprises at least about 90% by weight, for example about 90% to about 99% by weight, calcium carbonate. In practice this means, for example, if the granulation contains about 97% by weight calcium carbonate, no more than about 7% by weight of excipients and other ingredients should be added to the blend in preparing the tableting mix.
[0056] Referring again to Fig. 1, the dry granulation 401 is, in one embodiment, contacted with one or more excipients 403 including, for example, diluents or fillers, disintegrants or disintegrating agents, wetting agents, anti-adherents, glidants, lubricants, and/or other miscellaneous adjuncts such as colorants, and optionally with one or more additional nutritional or pharmaceutically active ingredients, for example vitamins such as vitamin D, in a blender 500 to form a tableting mix 501 which is then compressed into tablets with a tablet press 600.
[0057] Diluents such as starch or lactose are typically not required in preparing tablets according to the present invention, but small amounts, for example amounts that do not dilute calcium carbonate content of the tablets below about 90%, can be added if desired. [0058] One or more disintegrants can be included to assist breaking up of the tablet in the gastrointestinal tract after swallowing, and thereby accelerate dissolution to release calcium for intestinal absorption. Disintegrants can be generally be incorporated into the granulation (intragranular disintegrant) during the granulation process, or into the tableting mix prior to compression (extragranular disintegrant), or both. Examples of suitable disintegrants that can be used are starch, sodium starch glycolate, alginic acid, guar gum, croscarmellose sodium, crospovidone, ion exchange resins and combinations thereof. Tablets can illustratively contain about 1% to about 5%, for example about 1.5% to about 4% or about 2% to about 3%, by weight in total of one or more disintegrants, for example crospovidone, sodium starch glycolate and/or croscarmellose sodium.
[0059] One or more wetting agents can be included if desired, for example to assist in dispersion of the calcium carbonate in gastrointestinal fluid and thereby further accelerate dissolution. Wetting agents, if used, can be the same as or different from hydrophilic surfactants used in the granulation process as porosity increasing agents. For example, sodium lauryl sulfate is a useful wetting agent. Illustratively about 0.05% to about 0.5%, for example about 0.1% to about 0.25%, by weight of one or more wetting agents can optionally be added to the tableting mix.
[0060] Materials useful to improve flow characteristics of granulations, for example in preparing a tableting mix, are referred to as glidants. Suitable glidants include, for example, silicon dioxide, magnesium lauryl sulfate, magnesium aluminum silicate, magnesium oxide, talc, clays and combinations thereof. Glidants can be blended with the granulation to reduce inter-particulate friction and to eliminate problems associated with the flow of the tableting mix from larger to smaller apertures in a tablet press.
[0061] Lubricants may also be added to reduce friction and wear during processing. Some lubricants also demonstrate anti-adherent properties that can prevent the tableting mix from sticking during the tablet making process. Examples of suitable lubricants include magnesium stearate, talc, stearic acid, sodium stearyl fumarate, hydrogenated vegetable oil, high melting point waxes and combinations thereof.
[0062] Tablets can illustratively contain about 0.1% to about 2%, for example about 0.25% to about 1%, by weight in total of one or more glidants, lubricants and/or anti- adherents.
[0063] As indicated above, the relatively low density granulations of the invention can be compressed to form high density tablets having a high loading (at least about 90% by weight) of calcium carbonate. To achieve this, a compression force should be applied that is sufficient, in the particular tablet press fitted with the particular tablet dies to be used, to compress the tableting mix into a tablet having a density of at least about 2000 mg/cm3. One of ordinary skill in the art is able, by routine experimentation, to establish a suitable compression force for any particular tablet composition using any particular tableting equipment. Tablet density can be as high as about 2300 mg/cm3 or even higher; however, it is generally desirable to avoid excessively high tablet densities as these can lead to difficulties in
disintegration and dissolution. In addition, tablets compressed with excessive force can be excessively finable, and consequently do not stand up well to mechanical stresses during manufacture, packaging and shipping. In a particular embodiment, a compression force is selected to provide a tablet density of about 2100 to about 2200 mg/cm3.
[0064] Yet another embodiment of the invention provides a pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, including about 0.5% to about 5% by weight of binder present in the granulation before blending. Density of such a composition can be, without limitation, at least about 2000 mg/cm and can be as high as about 2300 mg/cm or even higher.
[0065] As referred to herein, the amount by weight of porosity increasing agent in a pharmaceutical or nutritional composition includes, for convenience, not only the amount added in the granulation process as described above, but also any amount of polyethylene glycol or hydrophilic surfactant optionally added as an excipient (e.g., as a wetting agent) to the tableting mix prior to compression.
[0066] In a preferred embodiment, the composition is a unit dosage form, in particular a compressed unit dosage form such as a tablet. "Tablets" herein embrace compressed dosage forms of any shape, including those elongated forms referred to in the art as "caplets". In various embodiments, a tablet of the invention can comprise about 92% to about 98%, for example about 94% to about 97%, by weight calcium carbonate. An illustrative pharmaceutical composition comprises at least about 95% by weight calcium carbonate and has a density of about 2100 to about 2200 mg/cm .
[0067] Tablets can be made in any desired size and shape but it is preferred that tablet volume is no greater than about 0.83 cm3. It can be calculated that a tablet having at least about 90% by weight calcium carbonate, and having a density of at least about 2000 mg/cm3 and a volume no greater than about 0.83 cm , can contain 600 mg calcium.
[0068] Unit dosage forms of the invention illustratively contain about 300 to about 600 mg calcium, in the form of calcium carbonate. In one embodiment, the pharmaceutical or nutritional composition is in tablet form and comprises about 600 mg calcium.
[0069] The combination of high calcium carbonate load (at least about 90% by weight)
and high density (at least about 2000 mg/cm3) enables a tablet composition of the invention containing about 600 mg calcium to have a volume of less than about 0.83 cm . The volume of such a tablet, in some embodiments, is about 0.67 to about 0.83 cm3, for example about 0.7 to about 0.8 cm3 or about 0.72 to about 0.77 cm3. Lower dose tablets, containing for example about 550 mg, about 500 mg, about 450 mg, about 400 mg, about 350 mg or about 300 mg calcium, can have proportionally lower volume.
[0070] For comparison, commercially available CALTRATE® 600 mg calcium tablets of Wyeth have been determined to have an average weight of about 1850 mg; based on a calcium carbonate amount of about 1500 mg (equivalent to 600 mg calcium) and assuming a moisture content of about 0.5%, the calcium carbonate loading of these tablets is calculated to be about 81.5% by weight. These tablets have further been determined to have a density of about 1950 mg/cm3 and an average volume of about 0.95 cm3.
[0071] In a particular embodiment of the present invention, the pharmaceutical or nutritional composition is in tablet form, comprises about 600 mg calcium and has a volume of less than about 0.76 cm3, for example about 0.72 to about 0.76 cm3. [0072] Thus, the present invention allows for the preparation of tablets comprising about 300 to about 600 mg calcium in the form of calcium carbonate, and having a volume that is about 15% to about 30% smaller than conventional calcium carbonate tablets such as CALTRATE® tablets.
[0073] Tablets prepared from the granulations of the present invention illustratively exhibit a breaking force of about 25 to about 30 Kp, a tablet density of from about 2100 to about 2200 mg/cm3, a friability of about 0.1% to about 0.4%, and a disintegration time of about 4 to about 8 minutes, all as measured using tests standard in the art. A 600 mg calcium tablet of the invention illustratively has a thickness of about 0.26 to about 0.27 inches (about 6.7 to about 6.9 mm) and a tablet weight of about 1540 to about 1640 mg. [0074] Pharmaceutical and nutritional compositions of the invention optionally further comprise one or more additional pharmaceutically or nutritionally active ingredients. In some embodiments, such additional ingredients comprise one or more vitamins or vitamin sources. In a particular embodiment, a composition of the invention comprises a vitamin D source such as vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol), which can enhance intestinal
absorption of calcium. Such additional ingredients can be added at any stage in the process of preparing a compositions including the granulation process, but typically it will be found most convenient to add such ingredients after granulation, when preparing a blend for example as a tableting mix. Some vitamins such as vitamin D are used in very small quantities and it can be advantageous to add them to the tableting mix in the form of dilute solutions in a suitable solvent, for example vegetable oil, polysorbate 80 or propylene glycol in the case of vitamin D3, or as a powder in mixture with a solid diluent such as sucrose, starch and/or dextrin.
[0075] In one embodiment, a calcium carbonate tablet of the invention, for example as described in detail above, comprising about 300 to about 600 mg calcium in the form of calcium carbonate, further comprises a vitamin D source, illustratively vitamin D3, in an amount of about 1 to about 30 μg, for example about 2.5 to about 25 μg, about 3 to about 20 μg or about 5 to about 15 μg per tablet, wherein 1 μg is equivalent to 40 IU vitamin D. [0076] A nutritional composition of the invention is useful in a method for supplementing calcium nutrition in a subject, the method comprising administering to the subject such a composition, for example one or more tablets, in an amount providing about 300 to about 1500 mg calcium per day, for example about 600 to about 1200 mg calcium per day. [0077] Calcium supplementation is advantageous not only where the diet is low in calcium, but also where hypocalcemia is caused or exacerbated by other factors. For example, calcium absorption into the circulatory system can be decreased by low levels of parathyroid hormone secretion (hypoparathyroidism), e.g., post-operative, autoimmune or congenital hypoparathyroidism, or reduced response to parathyroid hormone secretion (pseudohypoparathyroidism); magnesium depletion or extreme hypermagnesemia; or vitamin D deficiency. Calcium loss from the circulatory system can be increased, by hyperphosphatemia, for example associated with renal failure, rhabdomyolysis, tumor lysis or phosphate administration; acute pancreatitis; chelating agents such as citrate, lactate or EDTA; or osteoblastic metastases, for example in prostate or breast cancer. Other causal factors for hypocalcemia can include sepsis, excessive fluoride intake or surgery. [0078] Calcium absorption can be reduced or calcium loss increased as a side effect of certain drugs such as steroids (including steroidal hormones such as estrogen), proton pump
inhibitors (PPIs), certain antivirals such as foscarnet, or certain chemotherapeutics such as cisplatin, 5-fluorouracil or leucovorin. Thus in one embodiment, a composition of the invention is administered concomitantly with a drug such as a steroid, PPI antiviral or chemotherapeutic that reduces calcium absorption or increases calcium loss, the composition being administered in an amount effective to at least partly offset the reduced calcium absorption or increased calcium loss.
[0079] A pharmaceutical composition of the invention is useful in a method for treating or reducing risk of a medical disorder precipitated or aggravated by calcium deficiency and/or hypocalcemia in a subject, the method comprising administering to the subject such a composition, for example one or more tablets, in an amount providing about 300 to about 1500 mg calcium per day, for example about 600 to about 1200 mg calcium per day. [0080] Examples of medical disorders that can be precipitated or aggravated by calcium deficiency, particularly chronic calcium deficiency, and/or hypocalcemia include without restriction bone disorders including osteoporosis, osteomalacia and rickets; joint disorders; periodontal disorders; prostate or colorectal cancer; hypertension, for example systolic hypertension; kidney stones (due, for example, to excess calcium in urine associated with depletion of bone calcium); hyperlipidemia; cardiovascular and/or hemorrhagic disorders including stroke; menstrual disorders including premenstrual syndrome; miscarriage; birth, particularly heart, defects; obesity; sleep disorders; and mental, for example depressive, disorders.
[0081] In one embodiment, a composition of the invention is administered concomitantly with a drug that treats or alleviates a medical disorder precipitated or aggravated by calcium deficiency and/or hypocalcemia.
EXAMPLES
[0082] The following examples are merely illustrative, and do not limit this disclosure in any way.
Example 1
[0083] This example describes the preparation of a dry granulation comprising ground calcium carbonate, a binder and a porosity increasing agent.
[0084] The granulation was prepared in general accordance with the process illustrated in
Fig. 1 and described above. The experiment was begun by preparing a binder solution in a stainless steel mixer. The solution was prepared by adding heated water (263.75 g/min at 3O0C to 350C) to the vessel followed by binder (povidone K-90, 44.3 g/min). The binder was mixed at an impeller speed of about 7200 rpm until dissolved. Once the binder was dissolved, the mixing speed was reduced to about 2200 rpm and the porosity increasing agent (polysorbate 80, 1.85 g/min) was added slowly and mixed until dispersed. Mixing was continued for approximately 10 minutes to ensure that the porosity increasing agent was adequately dispersed. The resulting binder solution comprised 85.1% water, 14.3% binder and 0.6% porosity increasing agent.
[0085] The binder solution and calcium carbonate were then introduced into a continuous high shear paddle mixer (Turbulizer, Model TCS, Size 8 commercially available from Hosakawa Bepex, Minneapolis, MN) to produce a calcium carbonate granulation. The ground calcium carbonate (Calcipure™ calcium carbonate HD 212 USP/Ph. Eur., Code 9-4863) was fed into the continuous high shear paddle mixer at a controlled rate (1800 g/min) using a powder feeder (AccuRate Model No. 580-354600). The binder solution was introduced to the continuous high shear paddle mixer at a controlled rate (309.9 g/min) by means of a progressing cavity pump and spray nozzle. The mixer was operated continuously with an impeller speed of about 1900 rpm until the desired amount of granulation was produced. The material exiting the continuous high shear paddle mixer was continually monitored visually and evaluated for texture and moisture. The finished granulation was dried at approximately 450C to a moisture level of no more than 2% by weight. The resulting dried material was passed through an oscillator using a 20 mesh screen to remove any oversized particles.
[0086] The final dry granulation contained 97.5% ground calcium carbonate, 2.4% binder and 0.1% porosity increasing agent. The granulation exhibited a typical tapped density (1000 taps) of 0.9 g/ml. The granulation had a typical particle size (determined using a Tyler Ro-tap sieve shaker) as shown in Table 1.
Table 1
Example 2
[0087] This example describes the preparation of tablets comprising 600 mg calcium using the granulation described in Example 1.
[0088] The tablets were prepared by blending the calcium carbonate granulation prepared in Example 1 with crospovidone (20.6 mg/tablet), sodium starch glycolate (20.6 mg/tablet), magnesium stearate (7.91 mg/tablet) and sodium lauryl sulfate (3.17 mg/tablet) in a P-K twin shell blender. The total theoretical tablet weight was 1590.7 mg comprising 96.71% of the calcium carbonate granulation, 1.29% crospovidone, 1.29% sodium starch glycolate, 0.5% magnesium stearate and 0.2% sodium lauryl sulfate. Tablets were produced from the blend using 0.3125 inch X 0.7500 inch (approximately 7.5 mm X 18 mm) modified capsule shaped tooling at a compression force of approximately 42 kN. The tablets exhibited excellent tablet characteristics including high breaking force, low friability, low volume, high density, short disintegration time and fast dissolution rate, as shown in Table 2.
Table 2
Example 3
[0089] This example describes the preparation of tablets comprising 600 mg calcium with vitamin D3 using the granulation described in Example 1.
[0090] The tablets were prepared by blending the calcium carbonate granulation produced in Example 1 (1538.54 mg/tablet) with vitamin D3 (1.11 mg/tablet of a vitamin D3 powder containing 400 IU/mg, i.e., 11 μg vitamin D3/tablet), croscarmellose sodium (39.56 mg/ tablet), stearic acid (3.97 mg/tablet), magnesium stearate (3.97 mg/tablet) and sodium lauryl
sulfate (1.59 mg/tablet) in a P-K twin shell blender. The total theoretical tablet weight was 1588.7 mg, comprising 96.84% of the calcium carbonate granulation, 0.07% vitamin D3 solution, 2.49% croscarmellose sodium, 0.25% stearic acid, 0.25% magnesium stearate and 0.1% sodium lauryl sulfate. Tablets were produced from the blend using 0.3125 inch X 0.7500 inch (approximately 7.5 mm X 18 mm) modified capsule shaped tooling at a compression force of approximately 42 kN. The tablets exhibited excellent tablet characteristics including high breaking force, low friability, low volume, high density, short disintegration time and fast dissolution rate, as shown in Table 3.
Table 3
[0091] All patents and publications cited herein are incorporated by reference into this application in their entirety.
[0092] The words "comprise", "comprises", and "comprising" are to be interpreted inclusively rather than exclusively.
Claims
WHAT IS CLAIMED IS:
1. A granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent.
2. The granulation of Claim 1, wherein the calcium carbonate comprises ground calcium carbonate.
3. The granulation of Claim 2, wherein the ground calcium carbonate has a volume mean particle size of about 12 to about 22 μm.
4. The granulation of Claims 2 or 3, wherein the calcium carbonate is derived from a calcite form of calcium carbonate having a tapped density (1000 taps) of about 1400 to about 1700 mg/cm3.
5. The granulation of any of Claims 1 to 4, wherein the porosity increasing agent comprises polyethylene glycol and/or at least one pharmaceutically acceptable hydrophilic surfactant.
6. The granulation of any of Claims 1 to 4, wherein the porosity increasing agent comprises at least one pharmaceutically acceptable hydrophilic surfactant selected from the group consisting of sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, alkyl sulfates, sulfosuccinates, glyceryl fatty acid esters, polyglycol fatty acid esters, poloxamers, polyoxyethylene castor oil derivatives and combinations thereof.
7. The granulation of any of Claims 1 to 4, wherein the porosity increasing agent comprises polysorbate 80, docusate sodium and/or sodium lauryl sulfate.
8. The granulation of any of Claims 1 to 7, comprising
(a) about 97% to about 98% by weight calcium carbonate;
(b) about 1.5% to about 3% by weight of a binder; and
(c) about 0.05% to about 0.2% by weight of a porosity increasing agent comprising polyethylene glycol and/or at least one pharmaceutically acceptable hydrophilic surfactant.
9. The granulation of any of Claims 1 to 8, wherein the binder comprises at least one agent
selected from the group consisting of povidone, copovidone, hydroxypropylcellulose, HPMC, carmellose sodium and combinations thereof.
10. The granulation of any of Claims 1 to 8, wherein the binder comprises povidone.
11. The granulation of any of Claims 1 to 10, having a particle size distribution such that less than about 2% by weight of the granulation is retained by a 20 mesh sieve, about 30% to about 42% by weight of the granulation is retained by a 60 mesh sieve, about 55% to about 70% of the granulation is retained by a 100 mesh sieve, and at least about 80% by weight of the granulation is retained by a 200 mesh sieve.
12. The granulation of any of Claims 1 to 11, having a tapped density (1000 taps) of about 800 to about 1000 mg/cm3.
13. A granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of polyethylene glycol and/or at least one hydrophilic surfactant.
14. A process for preparing a calcium carbonate granulation, comprising
(a) contacting a calcium carbonate powder with water, a binder and a porosity increasing agent to form a homogeneous mix; and
(b) drying the mix; to provide a granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of the binder and about 0.03% to about 3% by weight of the porosity increasing agent.
15. The process of Claim 14, wherein the calcium carbonate comprises ground calcium carbonate.
16. The process of Claim 15, wherein the ground calcium carbonate has a volume mean particle size of about 12 to about 22 μm.
17. The process of Claims 15 or 16, wherein the ground calcium carbonate has a tapped density (1000 taps) of about 1400 to about 1700 mg/cm3.
18. The process of any of Claims 14 to 17, wherein, prior to said contacting, the water, porosity increasing agent and binder are mixed to form a binder solution.
19. The process of Claim 18, wherein the binder solution comprises about 80% to about 90% by weight water, about 10% to about 20% by weight binder, and about 0.2% to about 1.5% by weight porosity increasing agent.
20. A process for preparing a pharmaceutical or nutritional calcium composition, comprising
(a) contacting a calcium carbonate powder with water, a binder and a porosity increasing agent to form a homogeneous mix;
(b) drying the mix to provide a granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of the binder and about 0.03% to about 3% by weight of the porosity increasing agent;
(c) blending the granulation with one or more excipients to form a compressible blend; and
(d) compressing the blend to provide a pharmaceutical or nutritional calcium composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of the porosity increasing agent, and about 1% to about 10% by weight of other excipients.
21. The process of Claim 20, wherein said compressing provides a tablet comprising about 300 to about 600 mg calcium.
22. The process of Claim 21, wherein the tablet comprises at least about 93% by weight calcium carbonate.
23. The process of Claims 21 or 22, wherein, in said compressing, sufficient force is applied to provide a tablet having a density of about 2000 to about 2300 mg/cm .
24. The process of Claims 21 or 22, wherein, in said compressing, sufficient force is applied to provide a tablet having a density of about 2100 to about 2200 mg/cm3, and wherein the tablet comprises at least about 95% by weight calcium carbonate.
25. The process of any of Claims 20 to 24, wherein the granulation is further blended with a vitamin D source in an amount providing about 1 to about 30 μg vitamin D per tablet.
26. The process of Claim 25, wherein the vitamin D source comprises vitamin D3.
27. The process of any of Claims 20 to 26, wherein said excipient(s) blended with the granulation comprise one or more agents selected from the group consisting of diluents, disintegrants, wetting agents, anti-adherents, glidants, lubricants, colorants and combinations thereof.
28. The process of any of Claims 20 to 26, wherein said excipient(s) blended with the granulation comprise one or more agents selected from the group consisting of crospovidone, croscarmellose sodium, sodium starch glycolate, magnesium stearate, stearic acid, sodium lauryl sulfate and combinations thereof.
29. A pharmaceutical or nutritional composition comprising the granulation of any of Claims 1 to 13 and at least one extragranular excipient, wherein the composition comprises at least about 90% by weight calcium carbonate.
30. A pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients.
31. The composition of Claim 30 in a unit dosage form.
32. The composition of Claim 30, in the form of a tablet comprising about 300 to about 600 mg calcium.
33. The composition of Claim 32, wherein the tablet comprises at least about 93% by weight calcium carbonate.
34. The composition of Claims 32 or 33, having a density of about 2000 to about 2300 mg/cm3.
35. The composition of Claims 32 or 33, having a density of about 2100 to about 2200 mg/cm3.
36. The composition of Claim 35, wherein the tablet comprises at least about 95% by weight calcium carbonate.
37. The composition of any of Claims 30 to 36 in the form of a tablet comprising about 600 mg calcium and having a volume of less than about 0.83 cm3.
38. The composition of any of Claims 30 to 36 in the form of a tablet comprising about 600 mg calcium, having a density of about 2100 to about 2200 mg/cm3, and having a volume of less than about 0.76 cm .
39. The composition of any of Claims 30 to 38 in a unit dosage form further comprising a vitamin D source in an amount of about 1 to about 30 μg vitamin D per unit dosage form.
40. The composition of Claim 39, wherein the vitamin D source comprises vitamin D3.
41. The composition of any of Claims 30 to 40, wherein the other excipient(s) comprise one or more agents selected from the group consisting of binders, diluents, disintegrants, wetting agents, anti-adherents, glidants, lubricants, colorants and combinations thereof.
42. The composition of any of Claims 30 to 40, wherein the other excipient(s) comprise a binder that comprises at least one agent selected from the group consisting of povidone, copovidone, hydroxypropylcellulose, HPMC, carboxymethylcellulose sodium and combinations thereof.
43. The composition of any of Claims 30 to 40, wherein the other excipient(s) comprise one or more agents selected from the group consisting of povidone, crospovidone, croscarmellose sodium, sodium starch glycolate, magnesium stearate, stearic acid, sodium lauryl sulfate and combinations thereof.
47. A pharmaceutical or nutritional composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of polyethylene glycol and/or at least one hydrophilic surfactant, and about 1% to about 10% by weight of other excipients.
48. A method for supplementing calcium nutrition in a subject, comprising administering to the subject a composition comprising about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, in an amount providing about 300 to about 1500 mg calcium per day.
49. Use of a composition comprising about 90% to about 99% by weight calcium carbonate,
about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients, for preparation of a medicament to be administered to a subject in an amount providing about 300 to about 1500 mg calcium per day for treating or reducing risk of a medical disorder associated with calcium deficiency and/or hypocalcemia.
50. The use of Claim 49, wherein the disorder is selected from the group consisting of osteoporosis, osteomalacia, rickets, joint disorders, periodontal disorders; prostate and colorectal cancers, hypertension, kidney stones, hyperlipidemia, cardiovascular and hemorrhagic disorders, premenstrual syndrome, miscarriage, birth defects, obesity, sleep disorders, depressive disorders and combinations thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80017806P | 2006-05-12 | 2006-05-12 | |
US60/800,178 | 2006-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007134158A2 true WO2007134158A2 (en) | 2007-11-22 |
WO2007134158A3 WO2007134158A3 (en) | 2008-04-17 |
Family
ID=38694694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/068650 WO2007134158A2 (en) | 2006-05-12 | 2007-05-10 | Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy |
Country Status (3)
Country | Link |
---|---|
US (1) | US8859011B2 (en) |
AR (1) | AR061093A1 (en) |
WO (1) | WO2007134158A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009109988A2 (en) * | 2008-01-16 | 2009-09-11 | National Dairy Developement Board (Nddb) | Animal feed composition |
FR2947815A1 (en) * | 2009-07-10 | 2011-01-14 | Primex | Device for purifying the drinking water for ruminants, where the device has a solid shape and is formed from a solid concretion of calcium carbonate and sodium carbonate, which dissolves slowly and evenly until a desired pH is reached |
US8859011B2 (en) | 2006-05-12 | 2014-10-14 | Particle Dynamics International, Llc | Calcium compositions |
EP3520798A1 (en) | 2018-01-31 | 2019-08-07 | Omya International AG | Use of functionalized calcium carbonate as active ingredient |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7198653B2 (en) | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
UA95093C2 (en) | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Method for the preparation of calcium-containing compound |
US9138414B1 (en) * | 2006-09-15 | 2015-09-22 | Delavau Llc | Calcium supplement having enhanced absorption |
JP5689458B2 (en) * | 2009-05-13 | 2015-03-25 | ワイス・エルエルシー | Methods for stabilizing dietary supplements containing glucosamine |
PT2447328E (en) | 2010-10-29 | 2015-03-25 | Omya Int Ag | Method for improving handleability of calcium carbonate containing materials |
AR089857A1 (en) * | 2012-02-02 | 2014-09-24 | Glaxosmithkline Llc | COMPRESSED ANTICIDE TO COOL THE BREATH |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
US20050025811A1 (en) * | 2003-07-31 | 2005-02-03 | Raya Levin | Calcium carbonate granulation |
WO2006092727A2 (en) * | 2005-03-04 | 2006-09-08 | Nycomed Pharma As | Process for the production of calcium compositions in a continuous fluid bed |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1336328C (en) | 1988-04-11 | 1995-07-18 | Walter G. Leonard | Method of increasing bone density in humans |
US5424331A (en) | 1994-06-10 | 1995-06-13 | Bio-Virus Research Incorporated | Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis |
US6818228B1 (en) | 1996-06-21 | 2004-11-16 | Mission Pharmacal Company | Dietary supplements containing ultradense calcium citrate and carbonyl iron |
US20070003611A1 (en) | 2005-06-29 | 2007-01-04 | Sung-Tsuen Liu | Novel method of granulating calcium carbonate and products provided therefrom |
WO2007134158A2 (en) | 2006-05-12 | 2007-11-22 | Drugtech Corporation | Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy |
-
2007
- 2007-05-10 WO PCT/US2007/068650 patent/WO2007134158A2/en active Application Filing
- 2007-05-10 US US11/746,832 patent/US8859011B2/en active Active
- 2007-05-10 AR ARP070102031A patent/AR061093A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
US20050025811A1 (en) * | 2003-07-31 | 2005-02-03 | Raya Levin | Calcium carbonate granulation |
WO2006092727A2 (en) * | 2005-03-04 | 2006-09-08 | Nycomed Pharma As | Process for the production of calcium compositions in a continuous fluid bed |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8859011B2 (en) | 2006-05-12 | 2014-10-14 | Particle Dynamics International, Llc | Calcium compositions |
WO2009109988A2 (en) * | 2008-01-16 | 2009-09-11 | National Dairy Developement Board (Nddb) | Animal feed composition |
WO2009109988A3 (en) * | 2008-01-16 | 2010-04-29 | National Dairy Developement Board (Nddb) | Animal feed composition |
FR2947815A1 (en) * | 2009-07-10 | 2011-01-14 | Primex | Device for purifying the drinking water for ruminants, where the device has a solid shape and is formed from a solid concretion of calcium carbonate and sodium carbonate, which dissolves slowly and evenly until a desired pH is reached |
EP3520798A1 (en) | 2018-01-31 | 2019-08-07 | Omya International AG | Use of functionalized calcium carbonate as active ingredient |
WO2019149628A1 (en) | 2018-01-31 | 2019-08-08 | Omya International Ag | Use of functionalized calcium carbonate as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
US8859011B2 (en) | 2014-10-14 |
AR061093A1 (en) | 2008-08-06 |
US20070264329A1 (en) | 2007-11-15 |
WO2007134158A3 (en) | 2008-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8859011B2 (en) | Calcium compositions | |
AU2019204689B2 (en) | Solid dosage forms of palbociclib | |
JP5368802B2 (en) | Film-coated and / or granulated calcium-containing compounds and their use in pharmaceutical compositions | |
KR100898970B1 (en) | Particulate comprising a calcium-containing compound and a sugar alcohol | |
US7179486B1 (en) | Process for preparing sustained release tablets | |
JP2004506007A (en) | Method for producing tablets and tablet composition made therefrom | |
TWI625136B (en) | Oral formulations of deferasirox | |
JP5860286B2 (en) | Method for preparing a pharmaceutical composition comprising ezetimibe | |
AU1838100A (en) | Celecoxib compositions | |
WO2007029376A1 (en) | Orally rapidly disintegrating tablet | |
CN1162096C (en) | Potassium calcium citrate compositions and methods for production | |
JP2014051506A (en) | Preliminarily compressed calcium-containing composition | |
WO2013082706A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing | |
US20090054481A1 (en) | Saquinavir Mesylate Oral Dosage Form | |
WO1997033571A1 (en) | Rapid-release microdispersible ecadotril preparation | |
WO2015001329A1 (en) | Chewable tablet | |
WO2019012552A4 (en) | Compositions of ferric organic compounds | |
JP2023536094A (en) | A novel gastroretentive sustained release dosage form | |
JP2015155452A (en) | Burst drug release compositions | |
KR20170119651A (en) | High-loading, controlled-release magnesium oral dosage forms and methods for making and using same | |
CN113993506A (en) | Pharmaceutical dosage form comprising metformin and calcium citrate | |
WO2019012553A1 (en) | Process for preparation of compositions of ferric organic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07762083 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07762083 Country of ref document: EP Kind code of ref document: A2 |